Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy?

被引:9
作者
Furusato, B. [1 ,3 ]
Rosner, I. L. [2 ]
Osborn, D. [2 ]
Ali, A. [3 ]
Srivastava, S. [3 ]
Davis, C. J. [1 ]
Sesterhenn, I. A. [1 ]
McLeod, D. G. [2 ,3 ]
机构
[1] Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20306 USA
[2] Walter Reed Army Med Ctr, Dept Surg, Urol Serv, Washington, DC 20307 USA
[3] Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, Bethesda, MD 20814 USA
关键词
D O I
10.1136/jcp.2008.057794
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims: The objective of this study was to determine the incidence of prostate specific antigen (PSA) relapse in patients with low volume prostate cancer following radical prostatectomy. Methods: Between 1993 and 2001, 50 of 717 patients had total tumour volumes of less than 0.5 cm(3) following radical prostatectomy. Biochemical recurrence was defined as two consecutive values of serum PSA levels of 0.2 ng/ml or greater. Results: Median follow-up of the 50 patients was 58 months. In five of the 50 patients (10%), PSA recurrence was observed. All of these five cases had Gleason score of 3+3 (well and/or moderately differentiated), organ confined and surgical margin negative tumours. In three of the five cases, capsular incision resulted in benign glands extending into the surgical margin. Conclusions: Five of 50 cases had PSA failure. In three of the five patients, benign glands located in the margin could explain the "PSA recurrence". However, in the other two patients, none of the pathological parameters correlated with measurable PSA levels. The explanation for their PSA failure is unclear.
引用
收藏
页码:1038 / 1040
页数:3
相关论文
共 18 条
[1]   Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer [J].
Albertsen, PC ;
Hanley, JA ;
Gleason, DF ;
Barry, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :975-980
[2]   Insignificant prostate cancer in radical prostatectomy specimen: Time trends and preoperative prediction [J].
Augustin, H ;
Hammerer, PG ;
Graefen, M ;
Erbersdobler, A ;
Blonski, J ;
Palisaar, J ;
Daghofer, F ;
Huland, H .
EUROPEAN UROLOGY, 2003, 43 (05) :455-460
[3]   Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? [J].
Chan, TY ;
Chan, DY ;
Lecksell, K ;
Stutzman, RE ;
Epstein, JI .
JOURNAL OF UROLOGY, 2001, 166 (06) :2181-2184
[4]   Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens [J].
Cheng, L ;
Jones, TD ;
Pan, CX ;
Barbarin, A ;
Eble, JN ;
Koch, MO .
MODERN PATHOLOGY, 2005, 18 (08) :1022-1026
[5]   Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extraprostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients [J].
Desai, A ;
Wu, H ;
Sun, L ;
Sesterhenn, IA ;
Mostofi, FK ;
McLeod, D ;
Amling, C ;
Kusuda, L ;
Lance, R ;
Herring, J ;
Foley, J ;
Baldwin, D ;
Bishoff, JT ;
Soderdahl, D ;
Moul, JW .
PROSTATE CANCER AND PROSTATIC DISEASES, 2002, 5 (03) :212-218
[6]   The definition and preoperative prediction of clinically insignificant prostate cancer [J].
Dugan, JA ;
Bostwick, DG ;
Myers, RP ;
Qian, JQ ;
Bergstralh, EJ ;
Oesterling, JE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (04) :288-294
[7]   Impalpable invisible stage tie prostate cancer: Characteristics and clinical relevance in 100 radical prostatectomy specimens - A different view [J].
Elgamal, AAA ;
VanPoppel, HP ;
VandeVoorde, WM ;
VanDorpe, JA ;
Oyen, RH ;
Baert, LV .
JOURNAL OF UROLOGY, 1997, 157 (01) :244-250
[8]   PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER [J].
EPSTEIN, JI ;
WALSH, PC ;
CARMICHAEL, M ;
BRENDLER, CB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (05) :368-374
[9]   Nonpalpable stage T1c prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings [J].
Epstein, JI ;
Chan, DW ;
Sokoll, LJ ;
Walsh, PC ;
Cox, JL ;
Rittenhouse, H ;
Wolfert, R ;
Carter, HB .
JOURNAL OF UROLOGY, 1998, 160 (06) :2407-2411
[10]   Distinguishing clinically important from unimportant prostate cancers before treatment: Value of systematic biopsies [J].
Goto, Y ;
Ohori, M ;
Arakawa, A ;
Kattan, MW ;
Wheeler, TM ;
Scardino, PT .
JOURNAL OF UROLOGY, 1996, 156 (03) :1059-1063